Conscious Mind Labs Announces the Appointment of Neuroscientist Dr. Gregory E. Bigford as Chief Scientific Officer
The appointment further strengthens the company’s leadership position in developing psychedelic-related drugs for neurodegenerative diseases.
TORONTO, ON – TheNewswire - Mar. 2nd, 2021 – Conscious Mind Labs Inc., a revenue-focused and research-driven alternative medicine and mental health company, is pleased to announce the appointment of Dr. Gregory Bigford to the position of Chief Scientific Officer (CSO).
Dr. Bigford is a translational neuroscientist with more than a decade of experience in leading preclinical studies, pharmacological safety and efficacy and coordinating interventional clinical trials. Dr. Bigford is adept at working with diverse teams involving academic-industry partnership to design analyses, interpret complex data and lead development of publications and protocols that are currently being used as guideline approaches for intervention.
“Dr. Bigford’s background and relevant experience gives him the unique ability to apply neuroscience research and develop clinical applications and novel therapies for neurodegenerative diseases and mental health disorders,” says Donald Gauvreau, founder and CEO. “We are extremely excited to have Dr. Bigford join our team and lead our Psychedelic Drug Development Platform.” Dr. Bigford adds, “I plan on using my professional toolkit to develop research-based medicines and treatments that will ultimately improve mental health and accessibility for the general population.”
In addition to leading the company’s Psychedelic Drug Development Division, Dr. Bigford will oversee the Conscious Mind “R&D Hub,” the company’s foundation for innovation, along with the company’s CEO, Mr. Gauvreau, and Chief Medical Officer Dr. Jody Toor, an MD and board-certified integrative medicine doctor. “Our culturally diverse and inclusive leadership has decades of relevant experience in the fields of psychedelics, neuroscience, degenerative disease, drug development and mental health,” explains Mr. Gauvreau. “Conscious Mind is proud to be one of the most culturally diverse companies in this space, and we’re confident great results come from highly inclusive teams.”
Conscious Mind is investing significant resources into its proprietary Drug Development and Applied Research Platforms, and the appointment of Dr. Bigford to Chief Scientific Officer and transition of Dr. Toor to Chief Medical Officer further enhances the company’s leadership in these key areas. Conscious Mind has positioned itself as a revenue-focused and research-driven leader in the alternative medicine, mental health and mycology industries and continues to build the team needed to successfully execute on its short-term and long-term objectives.
About Conscious Mind Labs Inc.
Conscious Mind Labs Inc. is a revenue-focused and research-driven alternative medicine and mental health company. Conscious Mind discovers, researches and develops innovative medicines and therapy protocols to address mental health disorders and neurodegenerative diseases. Conscious Mind takes an integrated approach to deliver mental health solutions at scale through the development of research-proven psychedelic drugs and alternative medicines and “outside-the-box” treatment protocols tailored to different neurodegenerative diseases, including Alzheimer’s, dementia, Parkinson’s and mental health conditions, such as depression, PTSD and addiction. Conscious Mind is accelerating consumer access to alternative medicines and therapy through its Applied Research Platform, Clinics and TeleHealth application. Conscious Mind is positioning itself to deliver the world’s most comprehensive portfolio of alternative medicines and treatment solutions for neurodegenerative diseases and mental health disorders.
For further information, contact:
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future plans, programs, estimates, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “expects” or “does not expect”, “plans”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such uncertainties and risks include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; engaging in activities which currently are illegal under Canadian federal law and the uncertainty of existing protection from Canadian federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of use of psychedelic therapies, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of the financings contemplated herein; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.